AFMD Affimed N.V.

-0.1  -3%
Previous Close 3.45
Open 3.45
Price To Book 4.59
Market Cap 209140855
Shares 62,430,106
Volume 1,180,519
Short Ratio
Av. Daily Volume 955,712

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1b updated data due 2019.
AFM13 with Keytruda
Hodgkin Lymphoma - Cancer
Phase 2a ongoing.
Hodgkin Lymphoma - Cancer
Phase 1b/2a updated data due 2Q 2019.
CD30-positive lymphoma
Phase 1 trial placed on clinical hold - October 8, 2018. Expects to hear back from FDA during 2Q 2019.
Non-Hodgkin lymphoma (NHL) and acute lymphoblastic leukemia (ALL)
Phase 2 trial to be initiated 2Q 2019.
Relapsed/refractory peripheral T cell lymphoma (PTCL); transformed mycosis fungoides (TMF)

Latest News

  1. Affimed Provides Regulatory Update on AFM11 Clinical Program
  2. Implied Volatility Surging for Affimed (AFMD) Stock Options
  3. Edited Transcript of AFMD earnings conference call or presentation 27-Mar-19 12:30pm GMT
  4. Affimed Highlights AFM24 Innate Cell Engager Novel Mechanism of Action and Potential for the Treatment of EGFR-expressing Solid Tumors at the American Association for Cancer Research (AACR) 2019 Annual Meeting
  5. Affimed N.V. (AFMD) Q4 2018 Earnings Conference Call Transcript
  6. Affimed Reports 2018 Financial Results and Operational Progress
  7. Affimed Announces Full Year 2018 Financial Results Conference Call on March 27, 2019
  8. The Daily Biotech Pulse: FDA Nod For Roche And Amphastar, Milestone Payment Kicks In For Affimed
  9. Affimed Announces Milestone Payment from Genentech and ROCK® Platform Presentation at Innate Killer Summit 2019, Further Highlighting Leadership in Innate Immunity
  10. Will Affirmed Therapeutics (AFMD) Report Negative Q4 Earnings? What You Should Know
  11. Affimed to Present Data on AFM13 and AFM24 at AACR Annual Meeting 2019
  12. Affimed to Present at Upcoming Investor Conferences
  13. Trading Notes for Select Stocks
  14. Affimed to Present at the 37th Annual J.P. Morgan Healthcare Conference
  15. Do Options Traders Know Something About Affimed (AFMD) Stock We Don't?
  16. Affimed NV (AFMD): Are Hedge Funds Right About This Stock?
  17. Edited Transcript of AFMD earnings conference call or presentation 7-Nov-18 1:30pm GMT
  18. Affimed Announces U.S. Registrational Pathway and Updated Clinical Development Plan for AFM13 at R&D Day
  19. Affimed Presents Data at ASH 2018 Substantiating Opportunity for AFM13 as Mono- and Combination Therapy in CD30-Positive Tumors
  20. Affimed to Host Research & Development Day on Friday, December 7, 2018 in New York City